FOI Request
- Disclosure ID
- FOI/02881
- Request Date
- December 24, 2018
- Subject
- Compounded Bevacizumab
- Description
I am writing to make a request for information under the Freedom of Information Act.
- Does your Trust have, or intend to introduce, a policy that makes compounded bevacizumab routinely available to treat wet age-related macular degeneration?
If yes please supply a copy of your policy.
Thank you for your reply, could you confirm if your previous responses (02763 & 02881 Attached) still represents your Trust’s current position?
- Response
On 07/11/2018 our Trust responded to this same question from you as part of your FOI request 02763, question 4. Please refer to that response; I have attached a copy for your reference.
Following your request for clarification of our Trusts position regarding having, or intending to introduce, a policy that makes compounded bevacizumab routinely available to treat wet age-related macular degeneration, I contacted all relevant staff and departments for a definitive answer. I can now confirm Our Trust does not have any policy to use Bevacizumab in ophthalmology. Preliminary discussions have taken place to assess the possibility of using it in the future.
I trust this information satisfies your query, if not, please don’t hesitate to contact me.